Epidemiology

Human cases were first identified in 1970 in the Democratic Republic of Congo (DRC). Since then, cases have been increasing in humans, particularly in the DRC, which has reported cases continuously over that time. This increase in cases may be due to cessation of smallpox vaccination (which provided some cross-protection) or waning immunity, environmental factors (e.g., increased population density, human settlements in unknown animal reservoirs, deforestation), and/or genetic evolution of the virus. However, there is no evidence to support these theories.[4][5][6]

Mpox was previously known to be endemic in Central and Western Africa.[7]​ The majority of cases were reported in rural areas (adjacent to or within tropical forests) of the Congo Basin and western Africa, particularly in the DRC where a major outbreak occurred from 1996 to 1997.[5] 

  • Between 2000 and 2021, there were 95 suspected and 40 confirmed outbreaks in the Central African Republic, with the number of outbreaks increasing after 2018.[8]

  • Nigeria experienced a reemergence of cases in 2017 after 39 years without reports of cases. Since then, five outbreaks have occurred between 2017 and 2021.[9]

  • The largest outbreak of confirmed cases in the Central African Republic occurred in November 2021, with 14 cases and four waves of interhuman transmission.[10]

  • Outbreaks occurred in refugee camps in the Republic of Sudan in 2022, with no zoonotic origin reported.[11]

The current epidemiology of mpox is influenced by the specific clade of the virus.[1][12]

  • Clade Ia: found primarily in the DRC where it affects endemic provinces. It has increasingly been reported in previously unaffected provinces in recent years. Sporadic cases have been reported in the neighboring Central African Republic and Republic of Congo. Most cases are in children in the DRC and Central African Republic, with a higher proportion of cases among adults in the Republic of Congo.

  • Clade Ib: newly identified clade spreading predominantly in the eastern part of the DRC and its neighboring countries. Imported travel-related cases have been reported in countries outside of Africa. While most cases are in adults, there is a rising proportion of cases in children, likely driven by household transmission.

  • Clade IIa: outbreaks occurred in Cote d’Ivoire, Guinea, and Liberia in 2024. However, prior to this, human outbreaks had not been reported. Cases have been reported in adults and children. The most least described strain in the scientific literature.

  • Clade IIb: the cause of most outbreaks in West, North, and Southern Africa, as well as other parts of the world.

Several outbreaks of mpox have occurred since 2022, caused by different clades of the virus. These outbreaks are ongoing in many countries and have different modes of transmission and levels of risk.[1]

  • Prior to 2022, outbreaks were primarily reported in Central and Western Africa. However, a global outbreak of clade IIb mpox occurred in 2022 and continues to affect a number of countries.

  • Since 2023, outbreaks of clade Ia mpox and the newly identified clade Ib mpox have been occurring, primarily affecting the DRC and its neighboring countries.

  • Since 2024, there has been a significant increase in cases in Africa and detection of clade Ib mpox outside of Africa (mainly imported travel-related cases), prompting the World Health Organization (WHO) to declare a Public Health Emergency of International Concern (PHEIC) in August 2024.

Global clade IIb mpox outbreak

  • A global outbreak of clade IIb mpox was first identified in May 2022 and is ongoing across many countries. Clusters of cases were initially reported across several countries outside of Africa with no direct travel links to an endemic area. This was the first time that chains of transmission were reported in countries without known epidemiologic links to West and Central Africa.

  • The WHO declared that the outbreak constituted a PHEIC in July 2022. This PHEIC ended in May 2023 as the frequency of cases had decreased significantly, although cases continue to be reported.

  • Since the beginning of 2022, approximately 150,000 laboratory-confirmed cases were reported globally from 137 countries, including 380 deaths (as of 30 June 2025). The most affected countries were the US, the DRC, and Brazil.[13]

  • Unlike previous outbreaks, cases outside of Africa have predominantly been in younger adult men, most of whom identify as gay, bisexual, or other men who have sex with men.[14][15][16]​​ There is no signal suggesting sustained transmission outside of these networks.

  • Cases have also been reported in women (mainly heterosexual, including pregnant women) and children, albeit more rarely.[17][18][19]​​ In the US, 2.7% of all reported cases were in women including 3% in pregnant or recently pregnant women.[20]

  • In Nigeria, there were more cases in children and women, and fewer cases in people without HIV infection and gay, bisexual, or other men who have sex with men, compared with countries outside of Africa. Hospitalization rates were also much higher compared with other countries.[21]

  • Transgender and gender-diverse people have been disproportionately affected during the outbreak.[22][23]​​ Racial and ethnic disparities also exist.[24]

Clade I mpox outbreaks originating in Africa

  • ​​​​​​​There has been a significant increase in the number of cases and deaths in the DRC since 2023, with geographic expansion into previously unaffected areas (including neighboring countries such as Burundi, Kenya, Rwanda, and Uganda). The increase in cases in Africa is largely driven by outbreaks of the newly identified clade Ib virus in East African countries, including the DRC where the clade Ia virus is also co-circulating.[13]​​​​​​​

  • The WHO declared that the upsurge of mpox cases in Africa constituted a PHEIC on the 14th August 2024.[26]​​​

  • Approximately 49,000 laboratory-confirmed cases of mpox (both clades), including 213 deaths, were reported in Africa since the beginning of 2022 (as of 3 August 2025). Of these cases, approximately 41,000 were reported in the last 12 months, including 167 deaths, across 28 countries. The three countries with the majority of cases were the DRC, Uganda, and Sierra Leone.[13] The DRC reported approximately 88% of mpox cases in Africa in 2024.[27]​ The number of suspected cases is much higher; these cases remain untested due to limited diagnostic capacity in some African countries. 

  • The outbreaks of clade Ib mpox are ongoing, with sustained community transmission driven by sexual transmission. It is not currently known whether the circulating clade Ib variant is more transmissible or causes more severe disease compared with other clade I variants.[28][29]​ However, the clinical presentation of clade Ib mpox appears to be similar to the symptoms reported in the ongoing global clade II mpox outbreak, and differs from clade I outbreaks elsewhere in Africa.[30]

  • In eastern DRC, 67% of cases of clade Ib mpox were in people ages 15-30 years, while those ages <15 years only compromised 15% of cases.[31]​ In South Kivu, DRC, 14% of confirmed cases were in children ages <5 years, and 66% of cases were in individuals ages 15-34 years, with 48% of cases in women.[30]​ However, in Burundi, almost half of the confirmed clade Ib cases were in children ages <15 years, and 30% were in people ages between 15 and 29 years.[32]

  • A small number of cases of travel-associated clade Ib mpox have been reported outside of Africa including Australia, Belgium, Brazil, Canada, China, France, Germany, India, Ireland, Italy, Oman, Pakistan, Qatar, South Africa, Sweden, Switzerland, Thailand, Turkey, and the United Arab Emirates.[13]

​Current epidemiologic updates are available from public health authorities.

Prior to the 2022 global clade II mpox outbreak, outbreaks mainly affected children.[33]​ The median age at presentation has evolved from young children (4 years) in the 1970s to young adults (21 years) between 2010 and 2019.[4] In the 2022 global clade II mpox outbreak, male adults have been primarily affected and cases have been uncommon in children compared with adults.​[15][19]​​​​​​​​​​ Globally, 1.3% of cases were in children and adolescents ages <18 years and no deaths were reported.[34]​​ In the US, children and adolescents ages <18 years represented <0.01% of all cases and none resulted in critical illness or death. Cases have been reported rarely in neonates.​[35]​​

Available data from the 2022 global clade II mpox outbreak indicate that 28% to 51% of patients have been HIV-positive (in cases where HIV status is known).[36][37]​​​​​ Although women account for a minority of cases, the proportion of women with HIV has been estimated to be 27% (50% in transgender women).[38]​ However, in the largest study of women to date, only 4.4% of women had HIV (compared with 40.8% in men).[18]​ 

Prior to the 2022 global clade II mpox outbreak, a small number of travel-associated cases had been reported in the UK, the US, Singapore, and Israel.[39][40]​​​​​[41]​​[42][43][44][45][46][47]​​​ An outbreak of over 70 cases occurred in the US Midwest in 2003, and was the first reported occurrence of the disease outside of Africa. The source of this outbreak was exposure to infected prairie dogs that had acquired the infection from Gambian rats imported from West Africa.[48] ​

Use of this content is subject to our disclaimer